ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Código da empresaNDRA
Nome da EmpresaENDRA Life Sciences Inc
Data de listagemJun 28, 2017
Fundado em2007
CEOMr. Alexander Y. Tokman
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 28
Endereço3600 Green Ct Ste 350
CidadeANN ARBOR
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal48105-2440
Telefone17343350468
Sitehttps://www.endrainc.com/
Código da empresaNDRA
Data de listagemJun 28, 2017
Fundado em2007
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados